Listen on the go
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY
Neuro-ophthalmology

Ben Thompson, ARVO 2021: Latest Studies on Interventions for Visual Cortex Neuroplasticity

Share this Video
Copy Link
Published Online: May 13th 2021

It was a pleasure to catch up with Ben Thompson (University of Waterloo, Waterloo, ON, Canada), to discuss the latest clinical data on interventions for the enhancement of visual cortex neuroplasticity.

Questions

  1. What interventions enhancing visual cortex neuroplasticity are currently being investigated in humans with amblyopia? (00:15)
  2. Could you give us a brief overview of the latest clinical data supporting these interventions? (01:20)
  3. In which direction is future research likely to focus? (02:25)

Speaker Disclosure: Ben Thompson discloses the following: Two patents relating to binocular amblyopia treatment that have been licensed by Novartis. Two patents relating to assessment of children’s vision and co-founder of Objective Acuity, a company commercializing this technology. Paid consultancy for Novartis and Objective Acuity.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of ARVO 2021.

 

Related Videos In Neuro-ophthalmology
Neuro-ophthalmology
Developed by Touch
Mark Moster: RESCUE, REVERSE and RESTORE clinical trials: Investigating gene therapy for Leber’s hereditary optic neuropathy
Watch Time: 5 mins

Leber’s hereditary optic neuropathy (LHON) is characterized by bilateral, painless subacute loss of central vision during young adult life. We were delighted to speak with Prof. Mark Moster (Wills Eye Hospital, Philadelphia, PA, USA) to discuss the findings in the RESCUE, REVERSE and RESTORE clinical trials.  Questions: Could you give us a brief overview of […]

Neuro-ophthalmology
Ben Thompson, ARVO 2021: Latest Studies on Interventions for Visual Cortex Neuroplasticity

It was a pleasure to catch up with Ben Thompson (University of Waterloo, Waterloo, ON, Canada), to discuss the latest clinical data on interventions for the enhancement of visual cortex neuroplasticity. Questions What interventions enhancing visual cortex neuroplasticity are currently being investigated in humans with amblyopia? (00:15) Could you give us a brief overview of […]

Neuro-ophthalmology
Ben Thompson, ARVO 2021: Enhancement of Visual Cortex Neuroplasticity in Adults with Amblyopia

We spoke with Ben Thompson (University of Waterloo, Waterloo, ON, Canada) about neuroplasticity, and the relevance of visual plasticity in the treatment of amblyopia. Questions Could you give us a brief overview of neuroplasticity and its biological basis? (00:13) What manifestations of visual plasticity exist in the visual cortex of adults? (01:11) What is the […]

Trending In Neuro-ophthalmology:

Mark Moster: RESCUE, REVERSE and RESTORE clinical trials: Investigating gene therapy for Leber’s hereditary optic neuropathy
Neuro-ophthalmology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72